Bempedoic acid/ezetimibe not checked
FollowEvery change as it happens, and a Monday email
Trials
3 active
3 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia
- Main trialPhase 3
- “The overall objective of the trial is to evaluate the effect of the triple therapy consisting of bempedoic acid (BA), ezetimibe (EZE), and high-intensity atorvastatin or rosuvastatin on changes in coronary plaque burden and plaque morphology in patients with coronary atherosclerosis without significant obstructive coronary artery disease and without prior history of an ischemic vascular event.”In the company’s words, NCT07474649 on ClinicalTrials.gov
- Other names
- Bempedoic acid · Ezetimibe
Other drugs for Mixed Dyslipidemia
- ObicetrapibNewAmsterdam Pharma · Phase 3
- LaroprovstatAstraZeneca · Phase 3
- OlezarsenIonis Pharmaceuticals, Inc. · Phase 3
- ResmetiromMadrigal Pharmaceuticals, Inc. · Phase 3
- SHR-1918Hengrui · Phase 3
- Laroprovstat/rosuvastatinAstraZeneca · Phase 3
Coming up1
- 1 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 17 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07474649
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 1 Jun 2028 | A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events | |
| Phase 4Authorised | not given | Randomized clinical trial to assess the efficacy and safety of a strategy for primary prevention of cardiovascular disease in patients with inflammatory rheumatic diseases based on the use of carotid ultrasound. | |
| Phase 4Authorised | not given | Early LDL -cholesterol reduction in patients with acute coronary syndrome: a randomized clinical trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026